A Pilot Study of a Remote ADHD Monitoring Program
IDeA States Pediatric Clinical Trials Network · with Medical University of South Carolina, University of Mississippi Medical Center · NCT06743425
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 5–11 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 36
- US sites recruiting
- 2
- Study start
- February 4, 2025
- Record last updated
- April 28, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
RAMP is a pilot study examining the use of an Attention-Deficit/Hyperactivity Disorder (ADHD) Monitoring Program during the early stages of treating ADHD in children living in rural settings. This trial will enroll 36 caregiver/infant dyads across 2 sites and will evaluate feasibility endpoints rather than clinical outcomes. Enrolled participants will be randomized 1:1 to the intervention group (RAMP reports) or control group (digital education handouts). The study duration is 10 months, including start-up, enrollment and intervention, and data analysis and manuscript submission.
Being studied: RAMP Reports; Digital Education Handouts
Conditions: Attention-deficit/Hyperactivity Disorder; ADHD
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion Criteria
The child must
- be under the care of a participating provider
- be aged 5-11 at enrollment
- have a diagnosis of ADHD
- be initiating stimulant medication for treatment for the first time or have not received stimulant medication for the last 6 months
- be attending in-person elementary school
The Primary caregiver must
- be willing and legally able to give consent
- have access to a smartphone
- be English-speaking
- reside with the child at least 3 days per week
- complete an initial symptom assessment prior to starting stimulant treatment and be willing to provide a copy to the study team
The provider must
- manage ADHD care in patients age 5-11 years
- provide informed consent
- agree to use the RAMP platform if they care for patients randomized to use it
- agree to provide information to potential participants about the study and contact the research coordinator if interested
Exclusion Criteria
Child
- has serious mental health comorbidities (Children with depression, anxiety, oppositional defiant disorder will be permitted to participate. Children with schizophrenia, bipolar disorder, conduct disorder and those who have been hospitalized for any mental health condition will be excluded from the study.)
- has severe neurodevelopment disorders (Children with well-controlled seizure disorders will be permitted to participate.)
- is currently receiving, or previously received, atypical antipsychotic medication treatment
- is or becomes pregnant
Recruiting US locations
University of Mississippi Medical Center
Jackson, MS 39216
Site contact: Hannah Ford, PhD · 601-815-8413 · hford@umc.edu
Medical University of South Carolina
Charleston, SC 29425
Site contact: Claire MacGeorge, MD · 843-876-8512 · macgeorg@musc.edu
Study contacts (from the official record)
- Song Ounpraseuth, PhD · 501-686-7233 · STOunpraseuth@uams.edu
- Kripa Patel, BDS, MPH · (501) 686-5547 · kpatel@uams.edu
Similar studies in Mississippi
All mental health studies in Mississippi →- RecruitingHealthy volunteers
Observational Study of Decentralized Urine Optical Interaction Patterns Associated With Environmental Microplastic and Nanoplastic Exposure
Ecotera Health LLC
- Location
- Jackson, MS + 50 other US sites
- Eligibility basics
- Ages 18+
- Recruiting
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With…
LivaNova
- Location
- Flowood, MS + 49 other US sites
- Eligibility basics
- Ages 18+
- RecruitingPhase 3
A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)
Bristol-Myers Squibb
- Location
- Flowood, MS + 20 other US sites
- Eligibility basics
- Ages 18–65
- RecruitingPhase 3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
- Location
- Flowood, MS + 56 other US sites
- Eligibility basics
- Ages 55–90